Home: Fusion Energy - QLS Advisors LLC

Fusion Energy

Some text here!

Learn More

We combine data science, statistical inference, AI, and finance

Machine-learning techniques, statistical imputation, and natural language processing give more accurate forecasts of clinical trial outcomes, durations, probabilities of approval, and financial performance

Smarter financial decisions accelerate biomedical innovation

By managing risk through systematic portfolio construction methods, all biopharma stakeholders can lower the cost of capital and improve risk-adjusted returns, bringing more capital into this important sector

Finance doesn’t have to be a zero-sum game

Better financing structures and business decisions will help bring more therapies to patients faster and, ultimately, cheaper

Industry News

US DOE Milestone Program

The U.S. Department of Energy (DOE) today announced $46 million in funding to eight companies advancing designs and research and development for fusion power plants, representing a major step in President Biden’s commitment to a pilot-scale demonstration of fusion within a decade.

CFS Selected by US DOE

Milestone-Based Fusion Development Program award to accelerate innovation, leverage public and private sector resources towards development of fusion pilot plant

Lawrence Livermore National Laboratory Achieves Fusion Ignition

The U.S. Department of Energy (DOE) and DOE’s National Nuclear Security Administration (NNSA) today (Dec. 13) announced the achievement of fusion ignition at Lawrence Livermore National Laboratory (LLNL)

BlackRock and QLS Advisors Partner Through BlackRock Systematic to Invest in Biomedical Innovation

Strategies will focus on public and private companies developing potentially life-changing medical treatments Partnership combines the insights and scale of BlackRock’s active investment platform with QLS’s cutting-edge approach to investing in life sciences NEW YORK,...

BIO, QLS, and Informa Pharma Intelligence have released a new report on clinical development success rates covering 2011-2020

The report includes comparisons of success rates across indications and modalities, regulatory factors, and predictive factors driving successes and failures in drug development. This new data will help shape risk profiles and valuation metrics across investment and...

Informa Pharma Intelligence and QLS Partner to Pilot Predictive Analysis Tool for Clinical Trials

Partnership will help inform key decisions with new drug-level probability of approval scores powered by QLS and incorporated into Informa Pharma Intelligence’s Biomedtracker

Ask a Question

Want to know more? Send us a message!